60 related articles for article (PubMed ID: 20457255)
1. Baculovirus production of fully-active phosphoinositide 3-kinase alpha as a p85alpha-p110alpha fusion for X-ray crystallographic analysis with ATP competitive enzyme inhibitors.
Sinnamon RH; McDevitt P; Pietrak BL; Leydon VR; Xue Y; Lehr R; Qi H; Burns M; Elkins P; Ward P; Vincentini G; Fisher D; Grimes M; Brandt M; Auger KR; Ho T; Johanson K; Jones CS; Schwartz B; Sweitzer TD; Kirkpatrick RB
Protein Expr Purif; 2010 Oct; 73(2):167-76. PubMed ID: 20457255
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132
[TBL] [Abstract][Full Text] [Related]
3. Structure-based virtual screening approach to the discovery of phosphoinositide 3-kinase alpha inhibitors.
Park H; Choi H; Hong S; Kim D; Oh DS; Hong S
Bioorg Med Chem Lett; 2011 Apr; 21(7):2021-4. PubMed ID: 21354792
[TBL] [Abstract][Full Text] [Related]
4. The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations.
Huang CH; Mandelker D; Schmidt-Kittler O; Samuels Y; Velculescu VE; Kinzler KW; Vogelstein B; Gabelli SB; Amzel LM
Science; 2007 Dec; 318(5857):1744-8. PubMed ID: 18079394
[TBL] [Abstract][Full Text] [Related]
5. 4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase.
Traxler PM; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
J Med Chem; 1996 Jun; 39(12):2285-92. PubMed ID: 8691423
[TBL] [Abstract][Full Text] [Related]
6. Expression and purification of PI3 kinase alpha and development of an ATP depletion and an alphascreen PI3 kinase activity assay.
Boldyreff B; Rasmussen TL; Jensen HH; Cloutier A; Beaudet L; Roby P; Issinger OG
J Biomol Screen; 2008 Dec; 13(10):1035-40. PubMed ID: 19036708
[TBL] [Abstract][Full Text] [Related]
7. Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors.
McInnes C; Wang S; Anderson S; O'Boyle J; Jackson W; Kontopidis G; Meades C; Mezna M; Thomas M; Wood G; Lane DP; Fischer PM
Chem Biol; 2004 Apr; 11(4):525-34. PubMed ID: 15123247
[TBL] [Abstract][Full Text] [Related]
8. Structure/function analysis of a dUTPase: catalytic mechanism of a potential chemotherapeutic target.
Harris JM; McIntosh EM; Muscat GE
J Mol Biol; 1999 Apr; 288(2):275-87. PubMed ID: 10329142
[TBL] [Abstract][Full Text] [Related]
9. PDK1 and PKB/Akt: ideal targets for development of new strategies to structure-based drug design.
Harris TK
IUBMB Life; 2003 Mar; 55(3):117-26. PubMed ID: 12822887
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain.
Sawyer JS; Anderson BD; Beight DW; Campbell RM; Jones ML; Herron DK; Lampe JW; McCowan JR; McMillen WT; Mort N; Parsons S; Smith EC; Vieth M; Weir LC; Yan L; Zhang F; Yingling JM
J Med Chem; 2003 Sep; 46(19):3953-6. PubMed ID: 12954047
[TBL] [Abstract][Full Text] [Related]
11. Rapid evolution of 6-phenylpurine inhibitors of protein kinase B through structure-based design.
Donald A; McHardy T; Rowlands MG; Hunter LJ; Davies TG; Berdini V; Boyle RG; Aherne GW; Garrett MD; Collins I
J Med Chem; 2007 May; 50(10):2289-92. PubMed ID: 17451235
[TBL] [Abstract][Full Text] [Related]
12. Discovery and optimization of 2-(4-substituted-pyrrolo[2,3-b]pyridin-3-yl)methylene-4-hydroxybenzofuran-3(2H)-ones as potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR).
Tsou HR; MacEwan G; Birnberg G; Grosu G; Bursavich MG; Bard J; Brooijmans N; Toral-Barza L; Hollander I; Mansour TS; Ayral-Kaloustian S; Yu K
Bioorg Med Chem Lett; 2010 Apr; 20(7):2321-5. PubMed ID: 20188552
[TBL] [Abstract][Full Text] [Related]
13. Structural analysis of PI3-kinase isoforms: identification of residues enabling selective inhibition by small molecule ATP-competitive inhibitors.
Zvelebil MJ; Waterfield MD; Shuttleworth SJ
Arch Biochem Biophys; 2008 Sep; 477(2):404-10. PubMed ID: 18647592
[TBL] [Abstract][Full Text] [Related]
14. Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.
Hon WC; Berndt A; Williams RL
Oncogene; 2012 Aug; 31(32):3655-66. PubMed ID: 22120714
[TBL] [Abstract][Full Text] [Related]
15. Mechanism-based design of a protein kinase inhibitor.
Parang K; Till JH; Ablooglu AJ; Kohanski RA; Hubbard SR; Cole PA
Nat Struct Biol; 2001 Jan; 8(1):37-41. PubMed ID: 11135668
[TBL] [Abstract][Full Text] [Related]
16. Structure-guided discovery of cyclin-dependent kinase inhibitors.
Fischmann TO; Hruza A; Duca JS; Ramanathan L; Mayhood T; Windsor WT; Le HV; Guzi TJ; Dwyer MP; Paruch K; Doll RJ; Lees E; Parry D; Seghezzi W; Madison V
Biopolymers; 2008 May; 89(5):372-9. PubMed ID: 17937404
[TBL] [Abstract][Full Text] [Related]
17. WJD008, a dual phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin inhibitor, prevents PI3K signaling and inhibits the proliferation of transformed cells with oncogenic PI3K mutant.
Li T; Wang J; Wang X; Yang N; Chen SM; Tong LJ; Yang CH; Meng LH; Ding J
J Pharmacol Exp Ther; 2010 Sep; 334(3):830-8. PubMed ID: 20522531
[TBL] [Abstract][Full Text] [Related]
18. Structure-based drug design to the discovery of new 2-aminothiazole CDK2 inhibitors.
Vulpetti A; Casale E; Roletto F; Amici R; Villa M; Pevarello P
J Mol Graph Model; 2006 Mar; 24(5):341-8. PubMed ID: 16260160
[TBL] [Abstract][Full Text] [Related]
19. Structure-driven HtL: design and synthesis of novel aminoindazole inhibitors of c-Jun N-terminal kinase activity.
Stocks MJ; Barber S; Ford R; Leroux F; St-Gallay S; Teague S; Xue Y
Bioorg Med Chem Lett; 2005 Jul; 15(14):3459-62. PubMed ID: 15950471
[TBL] [Abstract][Full Text] [Related]
20. Design of new benzoxazole-2-thione-derived inhibitors of Streptococcus pneumoniae hyaluronan lyase: structure of a complex with a 2-phenylindole.
Rigden DJ; Botzki A; Nukui M; Mewbourne RB; Lamani E; Braun S; von Angerer E; Bernhardt G; Dove S; Buschauer A; Jedrzejas MJ
Glycobiology; 2006 Aug; 16(8):757-65. PubMed ID: 16638841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
